NRSN - NeuroSense Therapeutics Ltd Stock Price & Dividend Safety Sector: Healthcare | Exchange: NASDAQ Capital Market Current Price & Safety Score Price: 2.37 USD StockBonds Safety Grade: F Altman Z-Score (Bankruptcy Risk): -100.00 StockBond Score: -2.55 Company Description NeuroSense Therapeutics Ltd operates as a biotechnology firm in the clinical development phase committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions The companys leading drug candidate PrimeC is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis ALS Additionally its earlystage research pipeline features StabiliC a potential treatment for Parkinsons disease and CogniC which is under development for Alzheimers disease Established in 2017 NeuroSense Therapeutics Ltd is headquartered in Herzliya Israel